Ryan H. Nguyen
YOU?
Author Swipe
View article: Netherton Syndrome: A Systematic Review of the Challenges of Diagnosis and Treatment
Netherton Syndrome: A Systematic Review of the Challenges of Diagnosis and Treatment Open
View article: Open chromatin-guided interpretable machine learning reveals cancer-specific chromatin features in cell-free DNA
Open chromatin-guided interpretable machine learning reveals cancer-specific chromatin features in cell-free DNA Open
View article: “The more I know, the more you know” Using culturally responsive marketing strategies to develop tools that increase awareness about clinical trials among Black communities
“The more I know, the more you know” Using culturally responsive marketing strategies to develop tools that increase awareness about clinical trials among Black communities Open
Using marketing communication strategies is a low-tech, pragmatic approach to effectively produce health information that is meaningful, can be tailored for specific audiences, and disseminated to broader audiences.
View article: Obesity’s Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer
Obesity’s Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer Open
Data on COVID-19 outcomes in Asian Americans and Pacific Islanders (AAPI) are lacking. We analyzed data from 6,244 patients from the COVID-19 and Cancer Consortium, including 6.0% AAPI patients, to examine disparities in outcomes following…
View article: Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer Open
Importance: Non-Hispanic Black individuals experience a higher burden of COVID-19 than the general population; hence, there is an urgent need to characterize the unique clinical course and outcomes of COVID-19 in Black patients with cancer…
View article: Figure S5 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S5 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S5. KRAS/STK11 co-mutated tumors have an immune excluded phenotype via the xCell deconvolution algorithm
View article: Figure S6 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S6 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S6. KRAS mutated tumors have an increased CD cytotoxicity score, which is lost with STK11 co-mutation
View article: Figure S3 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S3 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S3. KRAS mutation is not associated with additional alterations to tumor immunogenicity
View article: Supplemental Figure Legends from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Supplemental Figure Legends from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Supplemental Figure Legends
View article: Figure S8 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S8 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S8. Tumor stage and PD-L1 expression independently associate with overall survival
View article: Figure S4 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S4 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S4. KRAS-induced CD8+ T-cell infiltration is unmodified by EGFR or BRAF status, but lost in LRP1B co-mutated tumors
View article: Figure S7 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S7 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S7F. Correlation between genes involved in lipid metabolism and those involved in immune processes
View article: Figure S2 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S2 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S2. KRASG12 mutations are associated with increased PD-L1 expression and CD8+ T-cell infiltration
View article: Figure S1 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S1 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S1. KRAS-induced PD-L1 expression is unmodified by EGFR, BRAF, or LRP1B status
View article: Exploring Mechanism of Action of Abemaciclib in Breast Cancer Through Circulating Chromatin Fragment
Exploring Mechanism of Action of Abemaciclib in Breast Cancer Through Circulating Chromatin Fragment Open
Cell free DNA (cfDNA) analysis has a large potential for cancer patient diagnosis. Given the evidence that cfDNA partially preserves chromatin architecture of tumor cells, it potentially allows the detection of tumor responses after therap…
View article: ATAC-seq Guided Interpretable Machine Learning Reveals Cancer-Specific Chromatin Features in Cell-free DNA
ATAC-seq Guided Interpretable Machine Learning Reveals Cancer-Specific Chromatin Features in Cell-free DNA Open
Cell-free DNAs (cfDNAs) are DNA fragments found in blood. In healthy individuals, cfDNAs are primarily derived from immune cells, while in cancer patients, a significant fraction of cfDNAs originates from cancerous cells. These cancer-deri…
View article: Comparative Analysis of Generative Pre-Trained Transformer Models in Oncogene-Driven Non–Small Cell Lung Cancer: Introducing the Generative Artificial Intelligence Performance Score
Comparative Analysis of Generative Pre-Trained Transformer Models in Oncogene-Driven Non–Small Cell Lung Cancer: Introducing the Generative Artificial Intelligence Performance Score Open
PURPOSE Precision oncology in non–small cell lung cancer (NSCLC) relies on biomarker testing for clinical decision making. Despite its importance, challenges like the lack of genomic oncology training, nonstandardized biomarker reporting, …
View article: A hybrid computer vision model to predict lung cancer in diverse populations
A hybrid computer vision model to predict lung cancer in diverse populations Open
PURPOSE Disparities of lung cancer incidence exist in Black populations and screening criteria underserve Black populations due to disparately elevated risk in the screening eligible population. Prediction models that integrate clinical an…
View article: Figure S6 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S6 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S6. KRAS mutated tumors have an increased CD cytotoxicity score, which is lost with STK11 co-mutation
View article: Figure S2 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S2 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S2. KRASG12 mutations are associated with increased PD-L1 expression and CD8+ T-cell infiltration
View article: Figure S3 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S3 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S3. KRAS mutation is not associated with additional alterations to tumor immunogenicity
View article: Figure S5 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S5 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S5. KRAS/STK11 co-mutated tumors have an immune excluded phenotype via the xCell deconvolution algorithm
View article: Figure S5 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S5 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S5. KRAS/STK11 co-mutated tumors have an immune excluded phenotype via the xCell deconvolution algorithm
View article: Data from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Data from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
As many as 30% of the patients with non–small cell lung cancer harbor oncogenic KRAS mutations, which leads to extensive remodeling of the tumor immune microenvironment. Although co-mutations in several genes have prognostic relevan…
View article: Figure S7 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S7 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S7F. Correlation between genes involved in lipid metabolism and those involved in immune processes
View article: Figure 1 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure 1 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Genetic landscape of cohort of patients with NSCLC. A, Tissue biopsies from 189 treatment-naïve patients with NSCLC, 114 of which were from the primary lung tumor, 31 from an affected lymph node, and 44 from a metastatic site, were …
View article: Figure S8 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S8 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S8. Tumor stage and PD-L1 expression independently associate with overall survival
View article: Figure 1 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure 1 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Genetic landscape of cohort of patients with NSCLC. A, Tissue biopsies from 189 treatment-naïve patients with NSCLC, 114 of which were from the primary lung tumor, 31 from an affected lymph node, and 44 from a metastatic site, were …
View article: Figure S4 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S4 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S4. KRAS-induced CD8+ T-cell infiltration is unmodified by EGFR or BRAF status, but lost in LRP1B co-mutated tumors
View article: Figure S7 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer
Figure S7 from Loss of <i>STK11</i> Suppresses Lipid Metabolism and Attenuates <i>KRAS</i>-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer Open
Figure S7F. Correlation between genes involved in lipid metabolism and those involved in immune processes